Loading
An early trial of JY231 run by Shenzhen Genocury Biotech Co., Ltd., now recruiting.
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia is an interventional study registered as NCT06678282 by Shenzhen Genocury Biotech Co., Ltd., with 20 participants planned, started 2023-09-07, primary completion expected 2026-09-30. Conditions recorded: B-NHL, B-ALL. Interventions recorded: JY231 Injection. The registry gives the phase as not applicable.
Shares JY231, Genocury Biotech, Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Genocury Biotech and the tag pipeline.
Shares Genocury Biotech and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/